Moderna reported strong Q3 2026 financial results, significantly exceeding analyst expectations, driven by robust COVID-19 vaccine demand. The company subsequently raised its full-year revenue growth outlook and improved its operating expense outlook, indicating strong financial performance and future growth prospects.
Moderna's Q3 2026 earnings report shows a 29% revenue increase and a GAAP net income of $0.2 billion, significantly outperforming analyst expectations. This strong performance, primarily due to international demand for its COVID-19 vaccine and strategic partnerships, led the company to raise its full-year 2026 revenue growth outlook from 10% to 15%-25% and improve its operating expense outlook. This is a major positive catalyst for MRNA stock, indicating strong current financial health and an optimistic future outlook, supported by new product approvals like mFLUSIVA and positive Phase 3 data for intismeran. Traders should see this as a strong buy signal in the short-term, with long-term implications for sustained growth in its pipeline.